CB1 receptor antagonists for the treatment of nicotine addiction

Pharmacology Biochemistry and Behavior

Volumn 81, Issue 2 SPEC. ISS., 2005, Pages 387-395

  Cohen, Caroline ^a   Kodas, Ercem ^a   Griebel, Guy ^a  

^a SANOFI   (France)

Author keywords

Addiction; Cannabinoid antagonist; Nicotine

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; 4 [6 METHOXY 2 (4 METHOXYPHENYL) 3 BENZOFURANYLCARBONYL]BENZONITRILE; 5 (4 BROMOPHENYL) 1 (2,4 DICHLOROPHENYL) 4 ETHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; DIHYDRO BETA ERYTHROIDINE; DOPAMINE RECEPTOR BLOCKING AGENT; ENDOCANNABINOID; MECAMYLAMINE; NICOTINE; RIMONABANT; SSR 591813; TOBACCO SMOKE; UNCLASSIFIED DRUG; NICOTINIC AGENT; NICOTINIC RECEPTOR;

ATTENUATION; CAUSE OF DEATH; CONFERENCE PAPER; DEVELOPED COUNTRY; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DRUG DEPENDENCE; DRUG EFFECT; DRUG EFFICACY; HUMAN; LIMBIC SYSTEM; MOTIVATION; NERVE CELL PLASTICITY; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; REWARD; SMOKING HABIT; ANIMAL; BRAIN LEVEL; DRUG ANTAGONISM; DRUG POTENTIATION; GENETICS; MOUSE; MOUSE MUTANT; REINFORCEMENT; REVIEW; SMOKING; TOBACCO DEPENDENCE;

NICOTIANA TABACUM;

ANIMALS; BRAIN CHEMISTRY; HUMANS; MICE; MICE, KNOCKOUT; NICOTINE; NICOTINIC AGONISTS; RECEPTOR, CANNABINOID, CB1; RECEPTORS, NICOTINIC; REINFORCEMENT (PSYCHOLOGY); SMOKING; TOBACCO USE DISORDER;

EID: 20444407166     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2005.01.024     Document Type: Conference Paper

References (78)

1. American Psychiatric Association Diagnostic and statistical manual of mental disorders 4th edition 1995 American Psychiatric Press Washington, DC
2. M. Arnone, J. Maruani, F. Chaperon, M.H. Thiebot, M. Poncelet, and P. Soubrie Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors Psychopharmacology (Berl) 132 1997 104 106
3. A.R. Caggiula, E.C. Donny, A.R. White, N. Chaudhri, S. Booth, and M.A. Gharib Environmental stimuli promote the acquisition of nicotine self-administration in rats Psychopharmacology (Berl) 163 2002 230 237
4. E. Carboni, A. Silvagni, M.T.P. Rolando, and G. DiChiara Stimulation of in vivo dopamine transmission in the bed nucleus of stria terminalis by reinforcing drugs J Neurosci 20 2000 U6 U10
5. A. Castane, E. Valjent, C. Ledent, M. Parmentier, R. Maldonado, and O. Valverde Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence Neuropharmacology 43 2002 857 867
6. J. Chao, and E.J. Nestler Molecular neurobiology of drug addiction Annu Rev Med 55 2004 113 132
7. C. Cohen, G. Perrault, C. Voltz, R. Steinberg, and P. Soubrie SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats Behav Pharmacol 13 2002 451 463
8. C. Cohen, O.E. Bergis, F. Galli, A.W. Lochead, S. Jegham, and B. Biton SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessation J Pharmacol Exp Ther 306 2003 407 420
9. C. Cohen, G. Perrault, G. Griebel, and P. Soubrie Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716) Neuropsychopharmacology 30 2005 145 155
10. G. Colombo, R. Agabio, M. Fa, L. Guano, C. Lobina, and A. Loche Reduction of voluntary ethanol intake in ethanol-preferring sP rats by the cannabinoid antagonist SR-141716 Alcohol Alcohol 33 1998 126 130
11. W.A. Corrigall, and K.M. Coen Selective dopamine antagonists reduce nicotine self-administration Psychopharmacology 104 1991 171 176
12. W.A. Corrigall, K.B. Franklin, K.M. Coen, and P.B. Clarke The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine Psychopharmacology 107 1992 285 289
13. G. Cossu, C. Ledent, L. Fattore, A. Imperato, G.A. Bohme, and M. Parmentier Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse Behav Brain Res 118 2001 61 65
14. D. Cota, G. Marsicano, M. Tschöp, C. Grübler Flachskamm, M. Schubert, and D. Auer The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis J Clin Invest 112 2003 423 431
15. R.I. Desai, D.J. Barber, and P. Terry Dopaminergic and cholinergic involvement in the discriminative stimulus effects of nicotine and cocaine in rats Psychopharmacology (Berl) 167 2003 335 343
16. G. Di Chiara Role of dopamine in the behavioural actions of nicotine related to addiction Eur J Pharmacol 393 2000 295 314
17. G. Di Chiara, and A. Imperato Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats Proc Natl Acad Sci U S A 85 1988 5274 5278
18. V. Di Marzo, C.S. Breivogel, Q. Tao, D.T. Bridgen, R.K. Razdan, and A.M. Zimmer Levels metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain J Neurochem 75 2000 2434 2444
19. E.C. Donny, A.R. Caggiula, M.M. Mielke, K.S. Jacobs, C. Rose, and A.F. Sved Acquisition of nicotine self-administration in rats: the effects of dose, feeding schedule, and drug contingency Psychopharmacology (Berl) 136 1998 83 90
20. M. Ezzati, and A.D. Lopez Estimates of global mortality attributable to smoking in 2000 Lancet 362 2003 847 852
21. L. Fattore, M.C. Martellotta, G. Cossu, M.S. Mascia, and W. Fratta CB1 cannabinoid receptor agonist WIN 55,212-2 decreases intravenous cocaine self-administration in rats Behav Brain Res 104 1999 141 146
22. C.C. Felder, K.E. Joyce, E.M. Briley, M. Glass, K.P. Mackie, and K.J. Fahey LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation J Pharmacol Exp Ther 284 1998 291 297
23. M.C. Fiore, W.C. Bailey, J.S. Cohen, S.F. Dorfman, M.G. Goldstein, and E.R. Gritz Treating tobacco use and dependence. US Department of Health and Human Services Clinical Practice Guideline 2000 US Department of Health and Human Services Washington
24. J.S. Fowler, N.D. Volkow, G.J. Wang, N. Pappas, J. Logan, and C. Shea Brain monoamine oxidase A inhibition in cigarette smokers Proc Natl Acad Sci U S A 93 1996 14065 14069
25. E.D. French delta9-Tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors Neurosci Lett 226 1997 159 162
26. Y. Gaoni, and R. Mechoulam J Am Chem Soc 86 1964 1646 1647
27. T.P. George, and S.S. O'Malley Current pharmacological treatments for nicotine dependence Trends Pharmacol Sci 25 2004 42 48
28. G.L. Gerdeman, J.G. Partridge, C.R. Lupica, and DM. Lovinger It could be habit forming: drugs of abuse and striatal synaptic plasticity Trends Neurosci 26 2003 184 192
29. S.R. Goldberg, and J.E. Henningfield Reinforcing effects of nicotine in humans and experimental animals responding under intermittent schedules of i.v. drug injection Pharmacol Biochem Behav 30 1988 227 234
30. S.R. Goldberg, R.D. Spealman, and D.M. Goldberg Persistent behavior at high rates maintained by intravenous self-administration of nicotine Science 214 1981 573 575
31. S. Gonzalez, M.G. Cascio, J. Fernandez-Ruiz, F. Fezza, V. Di Marzo, and J.A. Ramos Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine Brain Res 954 2002 73 81
32. A. Goodman Addiction: definition and implications Br J Addict 85 1990 1403 1408
33. A.J. Grottick, G. Trube, W.A. Corrigall, J. Huwyler, P. Malherbe, and R. Wyler Evidence that nicotinic alpha(7) receptors are not involved in the hyperlocomotor and rewarding effects of nicotine J Pharmacol Exp Ther 294 2000 1112 1119
34. D.M. Harvey, S. Yasar, S.J. Heishman, L.V. Panlilio, J.E. Henningfield, and S.R. Goldberg Nicotine serves as an effective reinforcer of intravenous drug-taking behavior in human cigarette smokers Psychopharmacology (Berl) 175 2004 518 519
35. J.E. Henningfield, E.D. London, and N.L. Benowitz Arterial-venous differences in plasma concentrations of nicotine after cigarette smoking J Am Med Assoc 263 1990 2049 2050
36. M. Herkenham, A.B. Lynn, B.R. de Costa, and E.K. Richfieldm Neuronal localization of cannabinoid receptors in the basal ganglia of the rat Brain Res 547 1991 267 274
37. B.L. Hungund, I. Szakall, A. Adam, B.S. Basavarajappa, and C. Vadasz Cannabinoid CB1 receptor knockout mice exhibit markedly reduced voluntary alcohol consumption and lack alcohol-induced dopamine release in the nucleus accumbens J Neurochem 84 2003 698 704
38. C. Ledent, O. Valverde, C. Cossu, F. Petitet, L.F. Aubert, and F. Beslot Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice Science 283 1999 401 404
39. B. Le Foll, and S.R. Goldberg Rimonabant, a CB1 antagonist, blocks nicotine-conditioned place preferences Neuroreport 15 2004 2139 2143
40. P. Mailleux, and J.J. Vanderhaeghen Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry Neuroscience 48 1992 655 668
41. D.H. Malin Nicotine dependence: studies with a laboratory model Pharmacol Biochem Behav 70 2001 551 559
42. H.D. Mansvelder, and D.S. McGehee Cellular and synaptic mechanisms of nicotine addiction J Neurobiol 53 2002 606 617
43. M.J. Marks, J.R. Pauly, S.D. Gross, E.S. Deneris, I. Hermans-Borgmeyer, and S.F. Heinemann Nicotine binding and nicotinic receptor subunit RNA after chronic nicotine treatment J Neurosci 12 1992 2765 2784
44. L.M. Marubio, A.M. Gardier, S. Durier, D. David, R. Klink, and M.M. Arroyo-Jimenez Effects of nicotine in the dopaminergic system of mice lacking the alpha4 subunit of neuronal nicotinic acetylcholine receptors Eur J Neurosci 17 2003 1329 1337
45. L.A. Matsuda, S.J. Lolait, M.J. Brownstein, A.C. Young, and T.I. Bonner Structure of a cannabinoid receptor and functional expression of the cloned cDNA Nature 346 1990 561 564
46. S. Munro, K.L. Thomas, and M. Abu-Shaar Molecular characterization of a peripheral receptor for cannabinoids Nature 365 1993 61 65
47. C.P. O'Brien Drug addiction and drug abuse L.S. Goodman A. Gilman The pharmacological basis of therapeutics 1996 Mc Graw Hill New York
48. S.R. Pagliusi, M. Tessari, S. DeVevey, C. Chiamulera, and E.M. Pich The reinforcing properties of nicotine are associated with a specific patterning of c-fos expression in the rat brain Eur J Neurosci 8 1996 2247 2256
49. S.L. Palmer, G.A. Thakur, and A. Makriyannis Cannabinergic ligands Chem Phys Lipids 121 2002 3 19
50. D.C. Perry, M.I. Davila-Garcia, C.A. Stockmeier, and K.J. Kellar Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies J Pharmacol Exp Ther 289 1999 1545 1552
51. R. Peto, A.D. Lopez, J. Boreham, M. Thun, C. Heath Jr., and R. Doll Mortality from smoking worldwide Br Med Bull 52 1996 12 21
52. M.R. Picciotto Nicotine as a modulator of behavior: beyond the inverted U Trends Pharmacol Sci 24 2003 493 499
53. M.R. Picciotto, M. Zoli, R. Rimondini, C. Lena, L.M. Marubio, and E.M. Pich Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine Nature 391 1998 173 177
54. E.M. Pich, S.R. Pagliusi, M. Tessari, D. Talabot Ayer, H.R. Hooft van, and C. Chiamulera Common neural substrates for the addictive properties of nicotine and cocaine Science 275 1997 83 86
55. M. Pistis, A.L. Muntoni, G. Pillolla, and G.L. Gessa Cannabinoids inhibit excitatory inputs to neurons in the shell of the nucleus accumbens: an in vivo electrophysiological study Eur J Neurosci 15 2002 1795 1802
56. F.E. Pontieri, G. Tanda, F. Orzi, and G. Di Chiara Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs Nature 382 1996 255 257
57. M. Rinaldi-Carmona, F. Barth, M. Heaulme, D. Shire, B. Calandra, and C. Congy SR141716A, a potent and selective antagonist of the brain cannabinoid receptor FEBS Lett 350 1994 240 244
58. M. Rinaldi-Carmona, F. Barth, C. Congy, S. Martinez, D. Oustric, and A. Perio SR147778, a new potent and selective antagonist of the CB1 cannabinoid receptor. Biochemical and pharmacological characterization J Pharmacol Exp Ther 310 2004 905 914
59. F.O. Risinger, and R.A. Oakes Nicotine-induced conditioned place preference and conditioned place aversion in mice Pharmacol Biochem Behav 51 1995 457 461
60. H. Rommelspacher, M. Meier-Henco, M. Smolka, and C. Kloft The levels of norharman are high enough after smoking to affect monoamineoxidase B in platelets Eur J Pharmacol 441 2002 115 125
61. Royal College of Physicians Nicotine Addiction in Britain A report of the Tobacco Advisory Group of the Royal College of Physicians 2000 Royal College of Physicians of London London
62. P.B. Sargent The distribution of neuronal nicotinic acetylcholine receptors F. Clementi D. Fornasari C. Gotti Neuronal nicotinic receptors Handbook of Experimental Pharmacology vol. 144 2000 163 192
63. G. Scherer Smoking behaviour and compensation: a review of the literature Psychopharmacology 145 1999 1 20
64. E. Schlicker, and M. Kathmann Modulation of transmitter release via presynaptic cannabinoid receptors Trends Pharmacol Sci 22 2001 565 572
65. M. Shoaib, I.P. Stolerman, and R.C. Kumar Nicotine-induced place preferences following prior nicotine exposure in rats Psychopharmacology 113 1994 445 452
66. M. Shoaib, C.W. Schindler, and S.R. Goldberg Nicotine self-administration in rats: strain and nicotine pre-exposure effects on acquisition Psychopharmacology 129 1997 35 43
67. I.P. Stolerman Inter-species consistency in the behavioural pharmacology of nicotine dependence Behav Pharmacol 10 1999 559 580
68. I.P. Stolerman, and M.J. Jarvis The scientific case that nicotine is addictive Psychopharmacology 117 1995 2 10
69. G. Tanda, F.E. Pontieri, and G. Di Chiara Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism Science 276 1997 2048 2050
70. G. Tanda, P. Munzar, and S.R. Goldberg Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys Nat Neurosci 3 2000 1073 1074
71. K. Tsou, S. Brown, M.C. Sanudo-Pena, K. Mackie, and J.M. Walker Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system Neuroscience 83 1998 393 411
72. US Department of Health and Human Services The health consequences of smoking: nicotine addiction Office on smoking and health 1988 US Government Printing Office Maryland, Washington DC
73. E. Valjent, J.M. Mitchell, M.J. Besson, J. Caboche, and R. Maldonado Behavioural and biochemical evidence for interactions between Delta 9-tetrahydrocannabinol and nicotine Br J Pharmacol 135 2002 564 578
74. S.S. Watkins, M.P. EppingJordan, G.F. Koob, and A. Markou Blockade of nicotine self-administration with nicotinic antagonists in rats Pharmacol Biochem Behav 62 1999 743 751
75. R.A. Wise Addictive drugs and brain stimulation reward Annu Rev Neurosci 19 1996 319 340
76. R.A. Wise, and M.A. Bozarth A psychomotor stimulant theory of addiction Psychol Rev 94 1987 469 492
77. S. Wonnacott, A. Drasdo, E. Sanderson, and P. Rowell Presynaptic nicotinic receptors and the modulation of transmitter release Ciba Found Symp 152 1990 87 101
78. World Health Organization International classification of diseases 10th edn 1992 WHO Geneva